Table 5sModel Parameters – Strong Heart Study4,16

ModelSHS (Men)SHS (Women)
AgeREF (45-54)
1.70 (1.33 - 2.17) (55-64)
2.58 (1.92 - 3.46) (65-74)
REF (45-54)
1.40 (1.09 - 1.80) (55-64)
2.03 (1.53 - 2.70) (65-74)
LDLREF (<100 mg/dL)
1.03 (0.76 - 1.39) (100-129 mg/dL)
1.67 (1.23 - 2.26) (130-159 mg/dL)
2.44 (1.72 - 3.47) (≥160 mg/dL)
REF (<100 mg/dL)
1.53 (1.15 - 2.04) (100-129 mg/dL)
1.61 (1.17 - 2.22) (130-159 md/dL)
2.17 (1.51 - 3.12) (≥160 mg/dL)
HDL1.31 (1.04 - 1.64) (<40 mg/dL)
REF (40-59 mg/dL)
0.84 (0.53 - 1.33) (≥60 mg/dL)
1.10 (0.86 - 1.40) (<40 mg/dL)
REF (40-59 mg/dL)
0.96 (0.69 - 1.33) (≥60 mg/dL)
Optimal BP (SBP < 120 & DBP < 80)REF (no Med use)REF (no Med use)
Pre-Hypertension (SBP 120 - 139, DBP 80-89) And No HTN Med Use1.78 (1.26 - 2.51)1.15 (0.83 - 1.59)
Hypertension Grades 1-4 (SBP >=140, DBP>=90) Or HTN Med Use2.01 (1.43 - 2.83)1.69 (1.25 - 2.28)
Diabetes Mellitus1.66 (1.30 - 2.12) (fasting glucose ≥126 or Med use)2.26 (1.73 - 2.96) (fasting glucose ≥126 or Med use)
Normal albuminuria (<30 albumin/creatinine urine ratio)(REF)(REF)
Microalbuminuria (ratio of urine albumin/creatinine was >30 and <300)1.39 (1.04 - 1.85)1.33 (1.00 - 1.77)
Macroalbuminuria (ratio of urine albumin/creatinine was >300)2.11 (1.51 - 2.95)2.69 (2.02 - 3.59)
Smoker1.38 (1.10 - 1.72) (Current)1.44 (1.14 - 1.83) (Current)

From: Appendix H, Summary Table 5

Cover of Systematic Review of Cardiovascular Disease Risk Assessment Tools
Systematic Review of Cardiovascular Disease Risk Assessment Tools [Internet].
Evidence Syntheses/Technology Assessments, No. 85.
Matheny M, McPheeters ML, Glasser A, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.